Compare Merck & Co., Inc. (MRK) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Oracle Corporation — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while Oracle Corporation trades at $128.01 (market cap $349.63B). The key difference: Merck & Co., Inc. and Oracle Corporation are close in size by market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | ORCL | |
|---|---|---|
Market Cap | $307.25B | $349.63B |
Sector | Health | Technology |
52-Week High | $129.52 | $328.33 |
52-Week Low | $77.60 | $121.37 |
Enterprise Value | $350.66B | $478.88B |
Dividend Yield | 2.73% | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Oracle (ORCL) trades at $126.48, up 1.78% today, with a strong fundamental backdrop including revenue growth to $57.40B in 2025 and a net income margin of 25.37%. Recent quarters have consistently beaten EPS estimates, and analyst consensus is bullish with a $253.30 price target. Technicals show a bearish overall signal but with bullish oscillators, and the stock faces support near $125.
The outlook is positive given Oracle's AI infrastructure expansion and earnings momentum, but risks include high debt levels and competitive pressures. The stock offers growth potential if execution continues, yet investors should weigh valuation multiples against sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
